A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Study Summary

The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).

Interventions

Study Locations

Facility	City	State	Country
City of Hope	Duarte	California	United States
Children's Hospital Los Angeles	Los Angeles	California	United States
Moffitt Cancer Center	Tampa	Florida	United States
Washington University	St Louis	Missouri	United States
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	United States
Vanderbilt University	Nashville	Tennessee	United States
University of Wisconsin	Madison	Wisconsin	United States
Peter MacCallum Cancer Centre	Melbourne	Victoria	Australia
Hospital Saint- Louis	Paris		France
University Hospital Robert Debre	Paris		France
Erasmus MC	Rotterdam		Netherlands
Prinses Maxima Centrum	Utrecht		Netherlands

Official Trial Information

View on ClinicalTrials.gov